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Summary
 
Background
 
Uterine leiomyomas are clinically signiﬁcant tumours
that may develop due to an altered differentiation pathway. We have
previously identiﬁed a dysregulated retinoic acid (RA) pathway that
reduced retinoic exposure in human leiomyoma surgical specimens,
and have shown that the leiomyoma phenotype was characterized
by excessive and disorganized extracellular matrix (ECM).
 
Objective
 
The goal of this study was to determine the impact of
RA exposure on the disrupted ECM phenotype of leiomyomas.
 
Design and methods
 
Study of immortalized and molecularly
conﬁrmed cells generated from surgical specimens of spontaneous
uterine leiomyoma and matched myometrium.
 
Results
 
Immortalized leiomyoma and myometrial cells retained
the molecular characteristics of their progenitor tissue. Proliferation
of leiomyoma cells was inhibited by all
 
-trans
 
 retinoic acid (ATRA).
Furthermore, there was a dose-dependent decrease in soluble extra-
cellular collagen protein in ATRA-treated leiomyoma cells. Exposure of
leiomyoma cells to ATRA resulted in a dose-dependent inhibition of
templates for speciﬁc ECM protein production including collagen 1,
collagen 4, ﬁbronectin and versican. Notably, expression levels in treated
leiomyoma cells approached those found in myometrial cells. These
mRNA alterations translated into altered protein. Down-regulation
was also observed among the RA pathway genes such as CYP26A1
with exposure to ATRA. Finally, ATRA down-regulated TGF-
 
β
 
3 mRNA
expression and the TGF-
 
β
 
 regulated genes in leiomyoma cells.
 
Conclusion
 
Exposure of leiomyomas to ATRA down-regulated
cell proliferation, ECM formation, RA metabolism and TGF-
 
β
 
regulation, suggesting that RA exposure can alter the leiomy-
oma phenotype to one that more closely approximates normal
myometrium.
(Received 5 September 2007; returned for revision 8 October 2007; 
 
ﬁnally revised 2 November 2007; accepted 15 November 2007)
 
Introduction
 
Uterine leiomyomas impact 20%–40% of women over 35 years of
age in United States.
 
1
 
 Enlargement of these tumours can cause pelvic
pain, menorrhagia, reduced fertility, pregnancy loss and a number
of other serious gynaecological problems. Women with symptomatic
leiomyoma may be obligated to undergo hysterectomy as it is the
only deﬁnitive treatment for this disease. As hysterectomy precludes
future childbirth, novel interventions are warranted to treat these
tumours.
Leiomyomas are oestrogen and progesterone responsive,
 
2
 
 but
gonadal hormones only promote growth, as GnRH agonist-induced
hypogonadism does not eliminate these tumours and the tumours
rapidly re-grow when gonadal hormone exposure resumes. Recently,
we have hypothesized that leiomyomas are a disease of differentiation
 
3
 
leading to a disrupted extracellular matrix (ECM). Altered differen-
tiation patterns in various normal tissues including keratinocytes
and neurones, as well as neoplasms such as leukaemia, ovarian
carcinoma and endometrial adenocarcinoma are known to be
inﬂuenced by retinoids.
 
4,5
 
 We have recently demonstrated that genes
involved in retinoic acid (RA) production were reduced in leiomy-
oma surgical specimens, while the RA metabolizing genes were
increased, resulting in a reduced amount of active RA.
 
6
 
 We also
demonstrated that the rate of RA metabolism is higher in leiomyoma
compared to myometrium tissue.
 
6
 
 Based on these ﬁndings, we
hypothesized that reduced intracellular all
 
-trans-
 
retinoic acid
(ATRA) concentrations in leiomyoma cells may result in alteration
of various signalling pathways that control its phenotype. Central to
the leiomyoma phenotype is the over-expression of ECM.
 
7
 
 In this
study, we determined whether exposure to ATRA impacts expression
of ECM genes and central signalling pathways in leiomyoma.
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Materials and methods
 
Immortalization of cell cultures
 
After obtaining IRB approval and consent from patients undergoing
medically indicated hysterectomy for symptomatic leiomyomas,
both myometrium and leiomyoma tissue were harvested at the
National Naval Medical Center, Bethesda, MD. The collection of
tissue and generation of primary cultures has been described
previously.
 
8
 
 The primary cultures of myometrium and leiomyoma
were immortalized using HPV-16 genes as described
 
9
 
 with
minor modiﬁcations. Brieﬂy, the primary cultures from ﬁrst pas-
sage were allowed to grow 40%–50% conﬂuence before infection
with retrovirus stock (pSLXN virus with genticin selection gene was
a gift from Dr Rhim, Center for Prostrate Disease Research,
Bethesda, MD). Polybrene (5 
 
μ
 
g/ml) was added to each ﬂask to
enhance infection by the retroviral vector. After incubation at 37 
 
°
 
C
for 24 h, the cells were washed once with PBS, heated to 37 
 
°
 
C
and cultured in fresh DMEM-F12 supplemented with 10% foetal
bovine serum (FBS). The cells were maintained at 37 
 
°
 
C and 5%
CO
 
2 
 
for 48 h before fresh media containing 100 
 
μ
 
g/ml of genticin
(G418, Sigma-Aldrich, St Louis, MO) was added. The cells were
grown for 4 days in selection media before fresh media was added.
The immortalized cells proliferated to conﬂuency before trypsini-
zation and further maintenance of the cells. Compared to primary
cultures that senesced at passage 10 and were no longer viable by
passage 12, the immortalized cells were growing well past passage
25.
 
Confirmation of E6 gene expression
 
To conﬁrm that the cells expressed HPV-16 E6 gene, end-point
reverse transcriptase polymerase chain reaction (RT-PCR) was per-
formed. RNA was isolated from both myometrial and leiomyoma
immortalized cells cultures using the TRIzol Reagent (Invitrogen,
Carlsbad, CA) according to manufacturer’s protocol and was
described previously.
 
6,8,10
 
Confirmation of cell cultures
 
The immortalized cell lines were conﬁrmed to be derived either from
myometrium or leiomyoma using the speciﬁc biomarker gene array
as described previously.
 
8
 
 Using real-time RT-PCR, expression of
the genes dermatopontin, versican, TGF-
 
β
 
3 and CYP26A1 were
analysed in the cell cultures.
 
Cell proliferation studies
 
Myometrial (1 
 
×
 
 10
 
3 
 
cells/well) and leiomyoma cells (1·5 
 
×
 
 10
 
3 
 
cells/
well) were plated in 96-well plates, and allowed to grow for 2 days
before being exposed to graded ATRA concentrations. Two plates for
each cell line was collected every 24 h for up to 96 h. The prolifera-
tion of the cells was measured using sulphorhodamine-B method
(Sigma-Aldrich) according to manufacturer’s protocol. Data repre-
sents three separate culture studies with six replicates of each
concentration per plate.
 
ATRA exposure
 
Immortalized myometrial and leiomyoma cells were plated at
densities of approximately 2 
 
×
 
 10
 
4
 
 cells/well in 6-well plates and
allowed to grow till 60% conﬂuency before exposure to ATRA at
10
 
–8
 
 
 
m
 
 to 10
 
–5
 
 
 
m
 
, as well as the vehicle-only control. The experiment
was repeated three times with duplicates at each concentration. After
24 h exposure to ATRA, the cells were lysed and RNA and protein
collected for further analysis. The media was collected, supplemented
with 1
 
×
 
 protease inhibitor (Pierce Biotechnology, Rockford, IL) before
storage at –80 
 
°
 
C for collagen analysis.
 
Soluble collagen expression
 
To determine soluble collagen, we used the SIRCOL method (Bicolor,
Accurate Chemical and Scientiﬁc Corp., Westbury, NY) according
to manufacturer’s recommendation, with modiﬁcations. The collec-
tion and storage of the media has been described above. On the day
of the experiment the media was thawed and collagen precipitated
by addition of 4 
 
m
 
 NaCl. After gentle rocking at 4 
 
°
 
C overnight, the
tubes were centrifuged at 20 000 
 
g
 
 for 40 min to pellet the collagens.
To generate a standard curve, known amounts of collagen (Type 1;
provided in the kit) underwent a similar precipitation procedure.
The pellet was dissolved in 0·5 
 
m
 
 acetic acid; the volume was the same
as the volume of starting media. Aliquots of 100 
 
μ
 
l for each sample
were taken in triplicate and Sircol dye reagent added. The tubes
were allowed to gently mix for 30 min at room temperature before
centrifugation at 15 000 
 
g
 
 for 10 min The collagen-dye pellet was
dissolved in alkali reagent supplied with the kit, and measured at
540 nm using Benchmark plus (Bio-Rad, Hercules, CA).
 
Reverse transcriptase polymerase chain reaction (RT-PCR)
 
End-point and real-time RT-PCR methods have been described
previously.
 
6,8,10
 
 Brieﬂy, the adherent cells were lysed using TRIzol,
and chloroform (0·2 ml per ml of TRIzol) was added. The samples
were centrifuged at 12 000 
 
g
 
 for 15 min at 4 
 
°
 
C. To the aqueous phase
ice-cold isopropanol was added at 0·5 ml per ml TRIzol to precipitate
RNA. The RNA pellet was washed once with 70% DEPC–ethanol,
brieﬂy dried and dissolved in DEPC-treated water. To ensure that
there was no contaminating DNA present, all RNA samples were
treated with DNAse-I enzyme using the DNA-free kit in accordance
to the manufacturer’s protocol (Ambion, Austin, TX). The RNA was
quantiﬁed spectrophometrically before storage at –80 
 
°
 
C.
For real-time RT-PCR, primers were synthesized in-house by Bio-
medical Instrumentation Center and the probes were synthesized by
Integrated DNA Technologies as described previously.
 
8
 
 Real-time
RT-PCR was done using iScript kit (Bio-Rad) and Bio-Rad 
 
i
 
C
 
ycler
 
software was used for data analysis.
 
Cytoimmunofluorescence
 
The method used was described previously with some modiﬁcations.
 
8
 
Brieﬂy, the cells were grown on glass chamber slides and treated with
ATRA (10
 
–7
 
 
 
m
 
) for 24 h. The cells were ﬁxed with cold methanol and
permeabilized with 0·2% Triton-X100 (Sigma-Aldrich). Nonspeciﬁc 
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sites were blocked using blocking buffer (1% BSA + 10% normal
goat serum) before addition of primary antibody (ﬁbronectin, Santa
Cruz Biotechnology, Santa Cruz, CA). After overnight incubation
at 4 
 
°
 
C the cells were washed with wash solution (PBS  +  0·05%
Triton + 1% BSA). Fluorescent secondary antibody conjugated with
Alexa-594 (Invitrogen) was used at recommended concentration
(1 
 
μ
 
g/ml). The mounting media (Vector Laboratories, Burlingame,
CA) contains the nucleic acid binding dye DAPI. The slides were
examined with an Axiovert 405M epiﬂuorescence inverted light
microscope (Carl Zeiss, Thornwood, NJ). Images were acquired with
a CCD camera (Orca-ER, Hamamatsu City, Japan).
 
Western blot
 
Protein was isolated using M-PER (Pierce Biotechnology) according
to manufacturer’s protocol. Protein was measured and stored at
–80 
 
°
 
C. The methodology has been described previously.
 
6
 
 Brieﬂy,
protein samples were denatured in 1
 
×
 
 SDS buffer before electro-
phoresis on SDS-PAGE gels (Invitrogen) and the separated proteins
were electro-blotted to nitrocellulose membrane. Versican V0/V1
Neo primary antibody (Afﬁnity Bioreagents, Golden, CO) was used
and detected with the horseradish peroxidase (HRP)-conjugated
secondary antibody (ImmunoPure, Pierce Biotechnology) in com-
bination with the SuperSignal West Pico (Pierce Biotechnology).
As an internal standard between the samples, antihuman 
 
β
 
-actin
(Santa Cruz Biotechnology) at a dilution of 1 : 50 000 was used.
 
Statistical analysis
 
All experiments were repeated a minimum of three times. For
real-time RT-PCR data, the results are reported as mean 
 
±
 
 SEM. For
each result the average expression of three replicates was calculated
before relative quantiﬁcation using normalization against house-
keeping gene (18S) was done. Relative expression was calculated
based on Pfafﬂ method.
 
11
 
 Wilcoxon signed rank test was used for
nonparametric statistical evaluation. For proliferation data, statistical
signiﬁcance was calculated by 
 
anova
 
 or student’s 
 
t
 
-test. Values below
 
P
 
 < 0·05 were considered signiﬁcant. For Western blot analysis,
calculations were done using Q
 
uality
 
O
 
ne
 
 software from Bio-Rad.
Data is presented as fold difference between leiomyoma and
myometrium (L : M) relative density units that was corrected
for internal control, 
 
β
 
-actin.
 
Results
 
Confirmation of Immortalized cell cultures
 
We developed immortalized cell cultures of leiomyoma and patient
matched myometrium by stably transfecting and expressing
HPV-16 E6/E7 genes as described previously.
 
9
 
 The E6 gene speciﬁc
product was observed in immortalized myometrial and leiomyoma
cells (data not shown). The RNA isolated from nontransfected
primary cultures did not demonstrate E6 gene product.
One of the most signiﬁcant challenges of primary cultures is the
loss of oestrogen receptor and progesterone receptor expression with
late passages. We therefore conﬁrmed that our immortalized cell
lines express oestrogen receptor and progesterone receptor in both
early and late passages (passages 7 and 14; data not shown).
We further validated leiomyoma from myometrial cultures based
on the molecular characteristics that distinguish leiomyoma from
the normal myometrium.
 
8
 
 The expression of dermatopontin was
markedly reduced in immortalized leiomyoma cells compared to
patient matched myometrial cells (–15·2 
 
±
 
 3·2-fold, 
 
P
 
 < 0·05).
Versican (3·05 
 
±
 
 0·79-fold, 
 
P
 
 < 0·05), CYP26A1 (19·16 
 
±
 
 3·98-fold,
 
P
 
 < 0·05)  and  TGF-
 
β
 
3 (2·6 
 
±
 
 1·02-fold, 
 
P
 
 < 0·05)  demonstrated
increased gene expression in leiomyoma cells, similar to the primary
cultures and progenitor tissue.
 
8
 
 Changes in expression of these genes
were maintained throughout multiple cell passages for both leiomy-
oma and myometrial cell cultures (data not shown).
 
Cell proliferation inhibited in response to ATRA exposure
 
Leiomyoma and myometrial cells treated with ATRA demonstrated
an inhibition of growth compared to untreated cells (Fig. 1). Statis-
tically signiﬁcant growth inhibition of leiomyoma cells occurred at
10
 
–8
 
 
 
m
 
 ATRA (Fig. 1a). Further growth inhibition was observed
at higher concentrations of ATRA. Myometrial cells demonstrated
signiﬁcant growth inhibition at 10
 
–6
 
 
 
m
 
 concentration (Fig.  1b).
These results suggest a greater sensitivity of leiomyoma cells to ATRA
compared with myometrial cells, resulting in growth inhibition at
Fig. 1 Leiomyoma and myometrial cells demonstrated ATRA 
concentration-dependent growth inhibition. Compared to control 
unexposed cells, signiﬁcant growth inhibition was observed at 10
–8 m and 
above in leiomyoma (a) and at 10
–6 m and above in myometrial cells (b). 
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10
 
–8
 
 
 
m
 
. This ﬁnding was unexpected, given the greater ability of
leiomyoma cells to metabolize ATRA to inactive compounds.
 
6
 
 We
therefore investigated the impact of ATRA treatment on expression
of genes involved in RA metabolism.
 
RA pathway genes regulated by ATRA treatment
 
RA regulates a number of genes involved in the RA pathway includ-
ing the receptors and metabolizing enzymes such as CYP26.
 
12–14
 
Up-regulation of CYP26A1 expression protects many cell types
from apoptosis.
 
15
 
 We have previously demonstrated that CYP26
genes were up-regulated in leiomyomas as compared to myometrial
tissue.
 
6
 
 Untreated leiomyoma cells (0 
 
μ
 
m
 
) demonstrated a 16·8 
 
±
 
4·5-fold up-regulation (
 
P
 
  <  0·05) of CYP26A1 gene expression
compared with myometrial cells (Table 1). At lower concentrations
of ATRA (10
 
–8
 
 
 
m
 
 and 10
 
–7
 
 
 
m
 
), CYP26A1 was down-regulated two
to fourfold in leiomyoma cells compared with myometrial cells.
At 10
 
–6
 
 
 
m
 
 and higher concentrations, the fold difference of expression
was similar in both leiomyoma and myometrial cell lines (0·91 
 
±
 
 0·02;
 
P
 
 < 0·05).
We have previously shown that cellular retinol binding protein
(CRBP-1) was down-regulated in leiomyoma tissue as compared to
myometrium.
 
6
 
 In this study, we have demonstrated that our immor-
talized cell lines also show a similar threefold down-regulation
of CRBP-1 mRNA expression (0·38 
 
±
 
 0·14; 
 
P
 
 < 0·05) in untreated
leiomyoma cells compared to myometrial cells (Table 1). A
concentration-dependent up-regulation of the gene was
observed on treatment with ATRA (Table 1). With 10
 
–8
 
 m ATRA
treatment, the expression of the CRBP-1 in leiomyoma was similar
to myometrial cells.
These results suggest that ATRA exposure at approximately 10
–8 m
can overcome the alterations in RA metabolism genes found in
leiomyomas, resulting in expression patterns comparable to
myometrial cells. Phenotypically, leiomyoma differs from normal
myometrium in the expression of excessive disorganized ECM.
3
We therefore evaluated total collagen expression in leiomyoma cells
when treated with ATRA.
ATRA exposure reduced collagen production
Leiomyomas are characterized by excessive collagen production in
the ECM.
7,16 We therefore evaluated the effect of ATRA treatment
on collagen production in leiomyoma cell cultures by measuring salt
soluble collagen secreted into the media after 24 h of ATRA treat-
ment, prior to one cycle of cell division. As shown in Fig. 2, leiomyoma
cells demonstrated a decrease in collagen secretion with increasing
ATRA exposure. At 10
–8 m ATRA, only 9 mg of soluble collagen was
measured in the media as compared to 15 mg in untreated cells.
ATRA regulated expression of individual ECM components
With a decrease in soluble collagen secretion, we hypothesized
that the expression of individual ECM components known to be
disrupted in leiomyomas may also be regulated by ATRA. We selected
collagen genes, based on previous work
16 that are known to be
differentially expressed in leiomyomas compared to myometrium.
The mRNA expression was increased for collagen genes COL1A1
(2·72 ± 0·55-fold; P < 0·05) and COL4A1 (2·95 ± 0·37-fold; P < 0·05)
in leiomyoma cells as compared to myometrial cells prior to treat-
ment (Fig. 3). With ATRA treatment, a down-regulation of collagen
Table 1. Regulation of leiomyoma : myometrial cell gene expression by retinoic acid
Genes analyzed
ATRA concentrations (m)
01 0
–8 10
–7 10
–6
RA genes
CRBP-1 0·38 ± 0·14 0·91 ± 0·13* 1·42 ± 0·19* 1·51 ± 0·38*
CYP26A1 16·81 ± 4·50 4·44 ± 1·46* 2·00 ± 1·08* 0·91 ± 0·02*
ECM genes
Collagen 1A1 2·72 ± 0·55 0·61 ± 0·14* 0·41 ± 0·04* 0·38 ± 0·18*
Collagen 3A1 1·99 ± 0·39 2·99 ± 1·31 2·50 ± 0·09 2·14 ± 0·29
Collagen 4A1 2·95 ± 0·37 0·89 ± 0·12* 1·13 ± 0·14* 1·33 ± 0·21*
Collagen 7A1 0·51 ± 0·11 0·56 ± 0·01 1·91 ± 0·17* 1·71 ± 0·12*
Fibronectin 2·18 ± 0·12 1·72 ± 0·41 1·62 ± 0·32 1·41 ± 0·23*
Versican V0 7·75 ± 2·2 7·73 ± 0·38 2·94 ± 0·43* 0·96 ± 0·04*
Versican V1 4·6 ± 0·45 0·71 ± 0·13* 0·70 ± 0·06* 0·19 ± 0·13*
Versican V3 8·32 ± 1·21 2·34 ± 0·68* 1·15 ± 0·22* 2·73 ± 0·13*
TGF-β pathway
TGF-β3 2·96 ± 0·71 0·84 ± 0·12* 0·12 ± 0·01* 0·09 ± 0·02*
MMP2 6·65 ± 1·22 0·56 ± 0·47* 0·36 ± 0·01* 0·67 ± 0·43*
Fold changes (leiomyoma : myometrial cell expression) in mRNA amount indicative of expression of genes that were analyzed in response to ATRA exposure. 
Experiments were performed in triplicate. Data are presented as mean ± SEM and were analyzed by Wilcoxon matched-pairs signed rank test. *Signiﬁcant 
difference (P < 0·05) compared to control (0 m). ATRA, all-trans-retinoic acid; RA, retinoic acid; ECM, extracellular matrix; CRBP-1, cellular retinol binding 
protein-1; TGF-β3, transforming growth factor β3; MMP2, matrix metalloproteinase.466 M. Malik et al.
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genes was observed. A fourfold down-regulation (0·61 ± 0·14-fold;
P < 0·05) of COL1A1 gene template was observed in leiomyoma
cells at concentration of 10
–8 m ATRA (Fig. 3a), with no further
signiﬁcant fold change at higher concentrations. COL4A1 template
also demonstrated a down-regulation of gene expression in treated
leiomyoma cells as compared to treated myometrial cells (Fig. 3b)
with greatest change at 10
–8 m ATRA (0·89 + 0·12; P < 0·05). At higher
concentrations of ATRA, the relative COL4A1 gene expression
between leiomyoma and myometrial cells remained comparable.
Collagen 7A1 (COL7A1) gene expression was lower (0·51 ± 0·11-
fold; P < 0·05) in leiomyoma cells in culture as compared to
myometrial cells in the absence of ATRA exposure (Table 1).
At ATRA concentrations of 10
–7 m, a twofold up-regulation of COL
7A1 gene expression was demonstrated with no further change in
expression at higher concentrations (Table 1).
Collagen 3A1 (COL3A1) template demonstrated an up-regulation
of gene expression (1·99 ± 0·39; P < 0·05) in untreated leiomyomas
compared to myometrial cells. We found that mRNA expression
of this collagen was unaffected by exposure to ATRA treatment
(Table 1).
Taken together, ATRA exposure reduced COL1A1 and COL4A1
mRNA expression in leiomyoma cells, approaching expression
patterns comparable to myometrial cells. The expression of COL7A1
template was increased by ATRA exposure, resulting in similar
comparable expression. However, not all collagens are altered
by ATRA exposure, as demonstrated with COL3A1 template
regulation.
Fibronectin expression in response to ATRA exposure
Fibronectin is an extracellular adhesion protein that binds to its
receptors on cell membrane and collagen in the matrix, thus anchor-
ing the cell. As shown in Table 1, untreated leiomyoma cells
demonstrated a 2·18 ± 0·12-fold (P < 0·05) increase in ﬁbronectin
mRNA expression compared to myometrial cells. With ATRA treatment,
leiomyoma cells demonstrated a down-regulation of ﬁbronectin
gene to levels comparable to myometrial expression patterns.
In order to conﬁrm that mRNA alterations translated into protein
alterations, we used cytoimmunoﬂuorescence to determine the
production of ﬁbronectin protein in leiomyoma and myometrial
cells in culture. In untreated leiomyoma cells, we demonstrated
a higher amount of ﬁbronectin protein in leiomyoma compared
with myometrial cells (Fig. 4). Post-treatment with 10
–7 m ATRA,
the leiomyoma cells (Fig.  4b) reduced ﬁbronectin protein.
Again, ﬁbronectin protein production in the presence of ATRA was
comparable between leiomyoma and myometrial cells.
Versican variants respond to ATRA treatment
Versican is an ECM proteoglycan that represses adhesion between
cells and plays a major role in many cellular processes in which tissue
remodelling of ECM is central.
17 Increased versican expression is
observed during pregnancy in cervix,
18 suggesting that increased
versican may characterize a loosely organized ECM. Dysregulated,
larger and loosely arranged ECM is a hallmark of leiomyomas
compared to surrounding myometrium.
3,16 We have previously
shown increased versican expression in leiomyoma cells compared
to myometrial cells in culture.
8 Based on the effect of ATRA on
Fig. 2 Effect of ATRA on secretion of collagens by leiomyoma cells. Reduced 
amount of collagens was secreted in the media of leiomyoma cells treated 
with ATRA. Soluble collagen was measured using the Sircol method. 
Signiﬁcant decrease in soluble collagens secreted (9 mg) was measured at 
10
–8 m ATRA as compared to 15 mg in untreated cells (0 m).
Fig. 3 Expression of collagens in leiomyoma and effect of ATRA treatment. (a) Collagen 1A1 ﬁbril template was elevated in leiomyoma (2·72 ± 0·55-fold; 
P < 0·05) as compared to myometrial cells and demonstrated a down-regulation at different concentrations of ATRA. (b) Collagen 4A1 ﬁbril template was 
elevated in leiomyoma (2·95 ± 0·37-fold; P < 0·05) and demonstrated a fold down-regulation at all concentrations of ATRA tested.ATRA alters ECM production in leiomyoma cells 467
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collagens and other ECM proteins, we hypothesized that ATRA
exposure would result in down-regulation of versican.
There are four isoforms of versican, V0, V1, V2 and V3, arising
due to differential gene splicing.
17,19 We demonstrated a 7·75-fold
increase (± 2·2; P < 0·05) of versican V0 mRNA expression in
leiomyoma cells as compared to myometrial cells (Table 1). There
was a marked decrease of versican V0 expression at 10
–7 m ATRA,
and by 10
–6 m ATRA the expression of V0 in leiomyoma and
myometrial cells was essentially at a 1 : 1 ratio (Table 1).
Similarly, versican V1 mRNA was 4·6 ± 0·45-fold elevated and
variant V3 was 8·32 ± 1·21-fold elevated in leiomyomas as compared
to myometrium in absence of ATRA exposure (Table 1). On exposure
to ATRA concentrations of 10
–8 m and greater, variant V1 was down-
regulated (0·71 ± 0·13; P < 0·05) in leiomyomas. Similarly, V3
demonstrated a down-regulation of the mRNA expression in
leiomyoma cells as compared to myometrial cells on exposure to
ATRA (Table 1). Versican variant V2 did not demonstrate statistically
signiﬁcant difference in untreated leiomyoma and myometrial cells,
although ATRA treatment down-regulated the mRNA expression
of this variant as well (data not shown).
To determine if changes observed at V0/V1 mRNA level translated
into changes in versican protein production, we used Western blot
analysis. As seen in Fig. 5, ATRA reduced the concentration of
versican protein in myometrial and leiomyoma cells. In untreated
cells, approximately fourfold higher protein concentration was seen
in leiomyoma cells as compared to myometrial cells. At ATRA
concentration of 10
–6 m, the amount of protein in leiomyoma was
close to the amount found in myometrium cells (1·14 ± 0·51-fold;
Fig. 5).
TGF-β3 gene expression is affected by ATRA treatment
Interaction between RA and the TGF-β pathway has been demon-
strated in different cell types, including Wilms tumour cells,
20 lung
cancer cells
21 and mesenchymal cells C3H10T1/2.
22 TGF-β pathway
also plays a major role in leiomyogenesis.
23,24 Expressions of all
TGF-β isoforms and receptors have been reported in both leiomyomas
and myometrium.
25–28 We and other laboratories have previously
demonstrated an increased expression of TGF-β3 in leiomyoma
compared to myometrium.
8,23,25,27,29,30 The TGF-β pathway is also
Fig. 4 Analysis of ﬁbronectin protein in myometrium and leiomyoma cells as analysed by cytoimmunoﬂuorescence. Pre-treatment leiomyoma cells (a) 
demonstrated a higher amount of protein (higher red ﬂuorescence) compared to myometrial cells (c). Decreased red ﬂuorescence in post ATRA (10
–7 m) 
treated leiomyoma cells (b) indicated a decreased amount of ﬁbronectin protein. Minimal decreased red ﬂuorescence was observed in myometrial cells (d). 
Red ﬂuorescence is indicative of ﬁbronectin protein, DAPI (blue ﬂuorescence) strongly binds to DNA and indicates the nucleus in the cell. Magniﬁcation: 40×.468 M. Malik et al.
Journal compilation © 2008 Blackwell Publishing Ltd, Clinical Endocrinology, 69, 462–470
No claim to original US government works
known to play a role in ECM remodelling in various tissues.
31 We
therefore hypothesized that leiomyoma cells exposed to ATRA would
demonstrate lower expression of TGF-β3 resulting in modulation of
TGF-β pathway as well as the TGF-β regulated genes.
In these studies, we have demonstrated that TGF-β3 mRNA was
signiﬁcantly elevated in untreated leiomyoma cells as compared
to myometrial cells (2·96  ± 0·92-fold;  P < 0·05).  We  observed  a
down-regulation of TGF-β3 mRNA in leiomyoma on exposure to
ATRA. As shown in Table 1, on exposure to 10
–8 m ATRA concen-
tration, the expression of TGF-β3 mRNA in leiomyoma cells was
similar to myometrial cells (0·84  ± 0·12;  P < 0·05),  indicating
that ATRA down-regulated the TGF-β3 expression and thus may
indirectly affect the TGF-β pathway.
To determine whether ATRA impacted the TGF-β pathway
regulation of speciﬁc genes, we examined the expression of matrix
metalloproteinase-2 (MMP-2) which is regulated by TGF-β in
leiomyomas.
32,33 As shown in Table  1, untreated leiomyoma cells
demonstrated a 6·65 ± 1·22-fold elevation of MMP-2 gene. At 10
–8 m
ATRA, down-regulation of MMP-2 was observed, resulting in
comparable expression in both cell lines. These results suggest that
ATRA may also affect the excessive and disorganized ECM expression
through the TGF-β pathway.
Discussion
Our results demonstrated that a rise in ATRA exposure impacted
leiomyoma cell proliferation and altered ECM production. Low
concentrations of ATRA (10
–8 m) inhibited growth of leiomyoma
cells in culture and regulated expression of leiomyoma cell ECM
structural components, proteoglycans, and cytokines to levels that
approximated expression patterns of myometrial cells. These results
suggest that the metabolic proﬁle identiﬁed in human leiomyomas
in-situ resulting in reduced exposure to active RA metabolites may
be critical in maintaining the leiomyoma phenotype.
The data from various laboratories on the impact of RA on
leiomyoma proliferation has been controversial. RA has been shown
to induce leiomyoma development in animal models for leiomyo-
mata.
30,34 Tsibris and coworkers
30 demonstrated that ATRA as well
as 9-cis-RA in the presence of E2-induced uterine leiomyoma
tumours. Using the Eker rat leiomyoma model, a genetic model
generated by the disruption tuberous sclerosis 2 gene expression,
Gamage and coworkers
34 demonstrated that use of retinoid X
receptor-selective agonist, LGD 1069, reduced the number of grossly
observable tumours due to increased apoptosis, but not the total
incidence, suggesting that RA agonists can inhibit leiomyoma growth.
In contrast, in vitro studies in primary cultures derived from human
leiomyoma suggested that augmentation of RA exposure led to
inhibition of cell growth.
35,36 Boetter-Tong and colleagues found that
ATRA inhibited leiomyoma and myometrial cell proliferation in
a reversible manner.
37 When these primary cell lines were treated
with RA, Mangioni demonstrated an inhibition of Wnt5b mRNA
production.
35 Retinoid analogue 4-(N-hydroxyphenyl)retinamide
(4-HPR) inhibited growth and induced apoptosis in primary
cultures derived from uterine leiomyomas without affecting
myometrial cell growth.
36 Given this controversy, and the limitations
of primary cultures, we generated novel immortalized and mole-
cularly conﬁrmed leiomyoma and myometrial cell lines to evaluate
the impact of RA.
In our study, at least a 10-fold higher concentration of ATRA was
required to observe signiﬁcant growth inhibition in myometrial cells.
ATRA at 10
–8 m is within the physiological dose
38 that has been
observed for various cellular activities including embryogenesis and
differentiation of different cell types, indicating that leiomyoma
tumours may respond to physiological and pharmacologically
relevant doses
38 of ATRA in vivo.
We had previously demonstrated that the rate of metabolism of
ATRA and 9-cis-RA was higher in leiomyoma tissue compared to
myometrium tissue.
6 Therefore, it was unexpected that growth of
leiomyoma cells responded to ATRA concentrations lower than those
required to see an effect in myometrial cells. Given the increased
activity of metabolizing enzyme CYP26A1 in leiomyoma cells,
8 we
expected that there would be greater metabolism of active ATRA
compound, thus negating the retinoid effect. Various investigators
have found a dose-dependent up-regulation of CYP26A1 by ATRA
in different cell types.
12,13 In leukaemia cells, ATRA can induce
CYP26A1 at doses of 1 μm,
12 whereas in endothelial cells, 10 μm
ATRA was required to induce expression of CYP26A1.
13 Our results
demonstrated that CYP26A1 transcripts were up-regulated in
myometrial cells exposed to ATRA when compared to unexposed
cells. In contrast, slight down-regulation of CYP26A1 was observed
in ATRA exposed leiomyoma cells when compared to unexposed
control cells. Signiﬁcant up-regulation of CYP26A1 in myometrial
cells and down-regulation in leiomyoma cells resulted in approximate
equal levels of CYP26A1 in these cells at 10
–6 m ATRA concentration.
Leiomyomas share phenotypic characteristics with normal
myometrium and ﬁbroblasts. While speculative, it is possible that
leiomyoma formation results from myometrial cells that undergo
altered differentiation that results in a phenotype deﬁned by excessive
and disorganized ECM production.
3 Retinoids are regulators of
differentiation in many cell types. In cultured stellate cells, it has been
demonstrated that ATRA can prevent morphological transition
towards a myoﬁbroblast phenotype and decrease collagen 1 synthesis.
37
In addition, ATRA can inhibit radiation-induced pulmonary ﬁbrosis.
39
The authors report inhibition of COL1A1 mRNA expression by
Fig. 5 ATRA treatment reduced the amount of versican protein in leiomyoma 
cells to an equivalent level of expression as myometrial cells. The fold difference 
between leiomyoma and myometrial cells (L : M) is based on differences in 
relative density measured using QualityOne software (Bio-Rad). 
The relative density units was corrected for internal control, β-actin.ATRA alters ECM production in leiomyoma cells 469
Journal compilation © 2008 Blackwell Publishing Ltd, Clinical Endocrinology, 69, 462–470
No claim to original US government works
ATRA in irradiated lung tissue. They further propose a role for
TGF-β pathway in pulmonary ﬁbrosis that is inhibited by ATRA.
Finally, redifferentiation, ECM synthesis and degradation is
regulated by ATRA in human arterial smooth muscle cells.
40
The mechanism of ATRA in leiomyoma cells that results in ECM
regulation remain speculative. ATRA is known to act through
different pathways including MAP kinase pathway
39,41,42 and protein
kinase C pathway.
39,43 In this study, we demonstrated an antiﬁbrotic
potential of ATRA on overall production of collagens secreted into
the ECM as well as the mRNA of collagen types 1, 3 and 4, ﬁbronectin
and versican in leiomyoma cells. At a dose of 10
–8 m ATRA, we
observed decrease in production of soluble collagens, indicating that
there may be changes in overall ECM production by leiomyoma cells.
TGF-β3 plays an important role in ECM accumulation. It is
known as an inducer of ECM proteins and its role in the pathogenesis
of ﬁbrosis is well established. Up-regulation of ECM deposition by
TGF-β pathway can take place through different mechanisms,
including stimulation of collagen synthesis and regulation of
MMPs.
31,32 Altered expression of TGF-β plays an important role in
leiomyogenesis
7,25–29 as demonstrated in vivo and in vitro. In leiomy-
omas, TGF-β regulation of ECM proteins such as collagens
23 and
ﬁbronectin,
26,27,29 and has also been demonstrated. Regulation
of TGF-β by retinoids has been demonstrated in various processes
such as chondrogenesis
44,45 and morphogenesis of the mammary
gland.
12 We have demonstrated an interaction between ATRA and
the TGF-β pathway in leiomyomas by demonstrating ATRA down-
regulation of TGF-β3 expression and expression of TGF-β regulated
genes such as the MMPs. We further hypothesize that both these
pathways may play a synergistic role in inducing the abnormal ECM
remodelling in leiomyogenesis and could potentially play a signiﬁcant
role clinically as combinational therapy for treatment for leiomyomas.
In summary, we have found that ATRA signiﬁcantly reduced
growth and synthesis of extracellular matrix proteins in leiomyoma
cells, and may exert some of its effect by regulating the TGF-β
signalling pathway.
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